Abstract:Introduction: The 2013 AHA/ACC Guideline recommended limiting saturated fatty acids (SFA) and substituting SFA with monounsaturated fatty acids (MUFA) or polyunsaturated fatty acids (PUFA) in diet. Dietary intake data derived from self-reports is prone to measurement error and studies have been criticized for this reason. An objective alternative approach to examining the role of different dietary fatty acids on coronary heart disease (CHD) risk is to measure plasma phospholipid fatty acid (PL-FA) profiles, which reflect both dietary intake and endogenous metabolism, hence are proximal to the pathophysiologic processes of CHD. Our aim was to evaluate the role of plasma PL-FA profiles on CHD risk both directly and by estimating the theoretical effects of plasma “substitution” of various fatty acids for each other on CHD risk, and evaluate the consistence with the AHA/ACC Guideline. Hypothesis: Plasma SFA is associated with increased CHD risk, and “substituting” plasma SFA with MUFA, PUFA n-6 or n-3 is associated with lower CHD risk. Methods: We performed a nested case-control study with 2428 postmenopausal women in Women’s Health Initiative Observational Study (1214 CHD cases-controls pairs matched for baseline age, enrollment date, ethnicity and hysterectomy). Plasma PL-FA profiles were measured using gas chromatography methodology and expressed as molar percentage (mol%). Multivariate conditional logistic regression was used to calculate ORs for CHD risk associated with 1 mol% PL-FA increase, and “substitutions” of various fatty acids for each other, adjusting for matching factors, physical activity, body mass index (BMI), smoking, family history of diabetes, anticoagulant medication, hormone therapy, hypertension, diabetes mellitus, dyslipidemia and alternative healthy eating index. In addition, we tested the interactions of BMI and hormone therapy with PL-FAs. Results: In multivariate conditional logistic regression analysis, plasma PL SFA was associated with increased CHD risk (OR=1.16, 95% CI 1.09 to 1.24) and PUFA n-3 was associated with decreased CHD risk (OR=0.92, 95% CI 0.86 to 0.97). No significant associations were observed for MUFA, PUFA n-6 and trans -fatty acids. “Substituting” 1 mol% SFA with an equivalent proportion of MUFA, PUFA n-6, or n-3 were associated with lower CHD risk (OR=0.81, 95% CI 0.74 to 0.88; OR=0.77, 95% CI 0.70 to 0.84;and OR=0.85, 95%CI 0.80 to 0.92, respectively). “Substituting” PUFA n-6 with n-3 was associated with lower CHD risk (OR=0.92, 95% CI 0.86 to 0.98) while no significant effect was found for “substituting” PUFA n-6 with MUFA. No significant interactions were obtained of BMI and hormone therapy with PL-FAs. Conclusion: This plasma PL-FA “substitution” analysis is consistent with the AHA/ACC Guideline and suggests that “substituting” PL SFA with MUFA, PUFA n-6 or n-3, and “substituting” PUFA n-6 with n-3 is associated with lower CHD risk.

Change in Plasma Phospholipid Fatty Acids over 13 Years and Determinants of Change: Epic-Norfolk Study

Changes in Plasma Phospholipid Fatty Acid Profiles over 13 Years and Correlates of Change: European Prospective Investigation into Cancer and Nutrition-Norfolk Study.

Plasma phospholipid very-long-chain SFAs in midlife and 20-year cognitive change in the Atherosclerosis Risk in Communities (ARIC): a cohort study

N‐6 Fatty Acids Instead of N‐3 and Saturated Fatty Acids Correlate with Body Fat Distribution from Subcutaneous Adipose Tissue to Visceral Adipose Tissue in Healthy and Overweight Subjects

The Occurrence of Trans-18:1 Isomers in Plasma Lipids Classes in Humans.

Serial circulating omega 3 polyunsaturated fatty acids and healthy ageing among older adults in the Cardiovascular Health Study: prospective cohort study

Abstract MP39: Plasma Phospholipid Fatty Acid and Coronary Heart Disease Risk

Plasma Phospholipid Fatty Acids and Coronary Heart Disease Risk: A Matched Case-Control Study Within the Women's Health Initiative Observational Study.

Relationship between erythrocyte phospholipid fatty acid composition and obesity in children and adolescents.

Association between plasma phospholipid saturated fatty acids and metabolic markers of lipid, hepatic, inflammation and glycaemic pathways in eight European countries: a cross-sectional analysis in the EPIC-InterAct study

Independent association between serum C-peptide levels and fat mass-to-lean mass ratio in the aging process.

Plasma Elaidic Acid Level as Biomarker of Industrial Trans Fatty Acids and Risk of Weight Change: Report from the EPIC Study

Plasma triacylglycerol length and saturation level mark healthy aging groups in humans

Lack of effect of meal fatty acid composition on postprandial lipid, glucose and insulin responses in men and women aged 50–65 years consuming their habitual diets

Undulating changes in human plasma proteome profiles across the lifespan

Dynamic lipidome alterations associated with human health, disease and ageing

Intra-individual variation of plasma trimethylamine-N-oxide (TMAO), betaine and choline over 1 year

Age-related changes in circadian regulation of the human plasma lipidome

Altered Plasma Amino Acids and Lipids Associated With Abnormal Glucose Metabolism and Insulin Resistance in Older Adults

Plasma Concentration of 36 (Poly)phenols and Prospective Body Weight Change in Participants from the EPIC Cohort

Plasma Protein Biomarkers of Healthy Dietary Patterns: Results from the Atherosclerosis Risk in Communities Study and the Framingham Heart Study